We also evaluated the combination with rosiglitazone in RT112 tumor xenografts using a second T cell donor (Supplementary Fig. 4i–k) as well as in HT1197 tumor xenografts (Fig. 4k, l), which are slower growing and express lower endogenous levels of NECTIN4. This evidence concerns the gene NECTIN4 and neoplasm.